Gary Schwartz, MD
Internal Medicine · Smyrna, TNNPI 1780694752
Payments from drug & device makers
Across 78 payments — averaging $17.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Orexo US, Inc.$184
- Indivior Inc.$168
- Lilly USA, LLC$141
- Novo Nordisk$94
- AstraZeneca$73
- Nevro Corp.$65
- plus $675 from 20 others
What the payments were for
- Food & beverage$1,401100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Orexo US, Inc. | 10 | $184 |
| Indivior Inc. | 9 | $168 |
| Lilly USA, LLC | 9 | $141 |
| Novo Nordisk | 6 | $94 |
| AstraZeneca | 5 | $73 |
| Nevro Corp. | 3 | $65 |
| Inspire Medical Systems, Inc. | 2 | $63 |
| Eisai Inc. | 4 | $58 |
| AbbVie | 3 | $58 |
| Jazz Pharmaceuticals Inc. | 3 | $56 |
| Astellas Pharma US Inc | 2 | $56 |
| Xeris Pharmaceuticals, Inc. | 2 | $49 |
| Pfizer | 2 | $38 |
| Vistapharm, Inc. | 3 | $37 |
| Neurocrine Biosciences, Inc. | 2 | $37 |
| Sunovion Pharmaceuticals Inc. | 2 | $32 |
| Kowa Pharmaceuticals America, Inc. | 2 | $30 |
| UCB, Inc. | 1 | $21 |
| Gilead | 1 | $21 |
| Amgen | 1 | $20 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Exact Sciences | 1 | $18 |
| Rhodes Pharmaceuticals L.p. | 1 | $16 |
| GSK | 1 | $15 |
| Merck | 1 | $15 |
| Vanda Pharmaceuticals Inc. | 1 | $15 |
How this compares
$1,401 in reported general payments places this provider in the 70th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 12 | $1,426 |
| Omeprazole | 18 | $358 |
| Rosuvastatin Calcium | 24 | $300 |
| Levothyroxine Sodium | 23 | $236 |
| Atorvastatin Calcium | 14 | $203 |
| Losartan Potassium | 13 | $141 |
| Gabapentin | 13 | $140 |
| Hydrochlorothiazide | 12 | $28 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Smyrna
- Mark McKenzieChattanooga$11.9M
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Obadias MarquezOoltewah$2.8M
- Amanda Moore MillerKnoxville$2.3M
- Rick WhilesBristol$1.5M
- John AndersonNashville$1.5M
- David MorinKingsport$1.4M
- John KirbyJefferson City$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.